HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target
CYTKNovember 18, 2024
Read more →Reported Saturday, Cytokinetics Unveils New Data On Aficamten And Hypertrophic Cardiomyopathy At AHA Scientific Sessions 2024
CYTKNovember 18, 2024
Read more →Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024
CYTKNovember 18, 2024
Read more →Cytokinetics Q3 EPS $(1.36) Misses $(1.26) Estimate, Sales $463.00K Miss $1.20M Estimate
CYTKNovember 6, 2024
Read more →Cytokinetics Plans Proposed Public Offering Of $500M Of Common Stock
CYTKMay 22, 2024
Read more →Cytokinetics And Royalty Pharma Enter Funding Collaboration; Cytokinetics To Receive $50M And Is Eligible To Draw Additional $175M Within 12 Months Of Aficamten Approval, Royalty Will Now Receive 4.5% Up To $5B Of Annual Net Sales Of Aficamten And 1% Abov
CYTKMay 22, 2024
Read more →'Amid Acquisition Speculation, Cytokinetics CEO Stresses Company Can Launch Heart Drug On Its Own' - STAT News
CYTKMay 17, 2024
Read more →Cytokinetics: Q1 Earnings Insights
CYTKCytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated earnings by 8.51%, reporting an EPS of $-1.02 versus an estimate of $-0.94.
May 4, 2022
Read more →Cytokinetics Q1 EPS $(1.05) Misses $(0.94) Estimate
CYTKMay 4, 2022
Read more →HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $75
CYTKApril 29, 2022
Read more →